著者

佐々木 学 梅垣 昌士 鶴薗 浩一郎 松本 勝美 芝野 克彦 呉村 有紀 米延 策雄

出版者

日本脊髄外科学会

雑誌

脊髄外科 (ISSN:09146024)

巻号頁・発行日

vol.30, no.2, pp.170-175, 2016 (Released:2016-09-03)

参考文献数

14

被引用文献数

2

---

Objective : Surgical site infection (SSI) caused by methicillin-resistant Staphylococcus aureus (MRSA) after spinal instrumentation surgery is often intractable, and removal of the implants is frequently necessary for infection control. Although vancomycin (VCM) has been most frequently used against SSI caused by MRSA, recent literatures questioned its efficacy because of its low tissue penetration. Some experts recommend combination therapy with anti-MRSA agents possessing higher tissue penetration or an anti-biofilm effect. The present report shows outcomes of antibiotic therapy for SSI caused by MRSA after spinal instrumentation surgery.  Materials and methods : From January 2011 to December 2013, four patients developed SSI caused by MRSA after spinal instrumentation surgery. Posterior lumbar interbody fusion was used in all patients. As initial therapy, VCM was given to one patient, and combined teicoplanin (TEIC) and rifampicin (RFP) were administered to the other three. These patients subsequently received therapy with TEIC, linezolid, or daptomycin combined with RFP, sulfamethoxazole-trimethoprim, or clindamycin. These agents were stopped sequentially if C-reactive protein remained negative for more than a week.  Results : Infection was uncontrolled in one patient initially treated with VCM, and removal of the posterior instrumentation and interbody cages was required for infection control. Combined therapy was given postoperatively, with complete cure by 13 weeks after removal of the implants. Infection was controlled and the implants could be retained in the other three patients who were initially treated with TEIC and RFP ; cure was achieved with subsequent combined therapy for 3-15 weeks.  Conclusion : The present study suggests that SSI caused by MRSA is treatable with retention of the implant by using combined therapy with anti-MRSA agents possessing higher tissue penetration than VCM or those with an anti-biofilm effect.